Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Acta Biomater ; 172: 67-91, 2023 12.
Artículo en Inglés | MEDLINE | ID: mdl-37806376

RESUMEN

The field of cancer immunotherapy has shown significant growth, and researchers are now focusing on effective strategies to enhance and prolong local immunomodulation. Injectable hydrogels (IHs) have emerged as versatile platforms for encapsulating and controlling the release of small molecules and cells, drawing significant attention for their potential to enhance antitumor immune responses while inhibiting metastasis and recurrence. IHs delivering natural killer (NK) cells, T cells, and antigen-presenting cells (APCs) offer a viable method for treating cancer. Indeed, it can bypass the extracellular matrix and gradually release small molecules or cells into the tumor microenvironment, thereby boosting immune responses against cancer cells. This review provides an overview of the recent advancements in cancer immunotherapy using IHs for delivering NK cells, T cells, APCs, chemoimmunotherapy, radio-immunotherapy, and photothermal-immunotherapy. First, we introduce IHs as a delivery matrix, then summarize their applications for the local delivery of small molecules and immune cells to elicit robust anticancer immune responses. Additionally, we discuss recent progress in IHs systems used for local combination therapy, including chemoimmunotherapy, radio-immunotherapy, photothermal-immunotherapy, photodynamic-immunotherapy, and gene-immunotherapy. By comprehensively examining the utilization of IHs in cancer immunotherapy, this review aims to highlight the potential of IHs as effective carriers for immunotherapy delivery, facilitating the development of innovative strategies for cancer treatment. In addition, we demonstrate that using hydrogel-based platforms for the targeted delivery of immune cells, such as NK cells, T cells, and dendritic cells (DCs), has remarkable potential in cancer therapy. These innovative approaches have yielded substantial reductions in tumor growth, showcasing the ability of hydrogels to enhance the efficacy of immune-based treatments. STATEMENT OF SIGNIFICANCE: As cancer immunotherapy continues to expand, the mode of therapeutic agent delivery becomes increasingly critical. This review spotlights the forward-looking progress of IHs, emphasizing their potential to revolutionize localized immunotherapy delivery. By efficiently encapsulating and controlling the release of essential immune components such as T cells, NK cells, APCs, and various therapeutic agents, IHs offer a pioneering pathway to amplify immune reactions, moderate metastasis, and reduce recurrence. Their adaptability further shines when considering their role in emerging combination therapies, including chemoimmunotherapy, radio-immunotherapy, and photothermal-immunotherapy. Understanding IHs' significance in cancer therapy is essential, suggesting a shift in cancer treatment dynamics and heralding a novel period of focused, enduring, and powerful therapeutic strategies.


Asunto(s)
Hidrogeles , Neoplasias , Humanos , Hidrogeles/uso terapéutico , Inmunoterapia/métodos , Neoplasias/patología , Linfocitos T , Terapia Combinada , Microambiente Tumoral
2.
Life Sci ; 285: 119947, 2021 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-34530016

RESUMEN

Electrospun nanofibers (NFs) were utilized to realize the dual-stage release of curcumin (Curc) to fully support the attachment, viability and proliferation of adipose-derived stem cells (hADSCs) with a delay in cellular senescence. For this purpose, both free Curc and Curc-loaded mesoporous silica nanoparticles (Curc@MSNs) were integrated into the electrospun polycaprolactone/gelatin (PCL/GEL) nanofibrous scaffolds and characterized via FTIR, BET, FE-SEM and TEM. In vitro drug release results demonstrated strong dual stage-discharge of Curc from the Curc/Curc@MSNs-NFs. Because of the combination of initial rapid release and late extended drug release, hADSCs cultured on the Curc/Curc@MSNs-NFs showed the greatest adhesion, metabolic activity and proliferation rate with a fibroblastic phenotype after 28 days of culture. Besides, a significant reduction in senescence-associated lysosomal α-L-fucosidase (SA-α-Fuc) expression and activity was also measured in hADSCs cultured on the Curc/Curc@MSNs-NFs. Moreover, not only the expression of hTERT in mRNA and protein levels was considerably increased in hADSCs seeded on the Curc/Curc@MSNs-NFs, but also the telomerase activity and telomere length were significantly enhanced in the scaffolds compared to the other types of scaffolds and control group. These results uncovered the potential of the two-stage discharge profile of Curc from Curc/Curc@MSNs-NFs to provide the biofunctionality of long-term cultured hADSCs for efficient stem cell-based regenerative therapies.


Asunto(s)
Tejido Adiposo/citología , Tratamiento Basado en Trasplante de Células y Tejidos/métodos , Senescencia Celular , Curcumina/administración & dosificación , Liberación de Fármacos , Células Madre Mesenquimatosas/efectos de los fármacos , Nanofibras/química , Nanopartículas/química , Animales , Adhesión Celular/efectos de los fármacos , Proliferación Celular , Células Cultivadas , Curcumina/farmacología , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Gelatina/química , Humanos , Células Madre Mesenquimatosas/citología , Células Madre Mesenquimatosas/fisiología , Ratones , Poliésteres/química , ARN Mensajero/biosíntesis , Dióxido de Silicio/química , Telomerasa/biosíntesis
3.
Arch Virol ; 166(10): 2649-2672, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34278528

RESUMEN

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, there is no effective therapeutic approach for treating SARS-CoV-2 infections. MicroRNAs (miRNAs) have been recognized to target the viral genome directly or indirectly, thereby inhibiting viral replication. Several studies have demonstrated that host miRNAs target different sites in SARS-CoV-2 RNA and constrain the production of essential viral proteins. Furthermore, miRNAs have lower toxicity, are more immunogenic, and are more diverse than protein-based and even plasmid-DNA-based therapeutic agents. In this review, we emphasize the role of miRNAs in viral infection and their potential use as therapeutic agents against COVID-19 disease. The potential of novel miRNA delivery strategies, especially EDV™ nanocells, for targeting lung tissue for treatment of SARS-CoV-2 infection is also discussed.


Asunto(s)
COVID-19/terapia , MicroARNs/administración & dosificación , SARS-CoV-2/fisiología , COVID-19/metabolismo , COVID-19/virología , Sistemas de Liberación de Medicamentos , Diseño de Fármacos , Exosomas/metabolismo , Genoma Viral , Humanos , MicroARNs/metabolismo , Proteínas Virales/metabolismo , Replicación Viral
4.
Mater Sci Eng C Mater Biol Appl ; 116: 111225, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32806312

RESUMEN

Zeolites are crystalline, hydrated aluminosilicates of alkali earth cations, consisting of 3D frameworks of [SiO4]4- and [AlO4]5- tetrahedral, linked through the shared oxygen atoms, which have been widely applied in multifarious technological approaches such as adsorbents, catalysts, ion exchangers, molecular sieves for separation, and sorting the molecules according to their crystalline size dimensions. On the other hand, the unique and outstanding physical and chemical properties of zeolite materials such as porous character, ion exchangeability, water absorption capacity, immunomodulatory and antioxidative effects, biocompatibility and long-term chemical and biological stability, make them increasingly useful in various filed of biomedicine including drug delivery systems, wound healing, scaffolds used in tissue engineering, anti-bacterial and anti-microbial, implant coating, contrast agents, harmful ions removal from the body, gas absorber, hemodialysis, and teeth root filling. Therefore, this review focuses on the more recent advances of the use of zeolites in various biomedical applications feedbacks especially drug delivery, regenerative medicine, and tissue engineering with special emphasis on their biomaterial perspectives.


Asunto(s)
Zeolitas , Materiales Biocompatibles , Sistemas de Liberación de Medicamentos , Medicina Regenerativa , Ingeniería de Tejidos
5.
Int J Pharm ; 587: 119656, 2020 Sep 25.
Artículo en Inglés | MEDLINE | ID: mdl-32687972

RESUMEN

The present research aims to design and develop a sustained drug release system to support the long-term proliferation of human adipose-derived stem cells (hADSCs) without losing their stemness and entering the cellular senescence through providing typical cell culture conditions. For this purpose, Curcumin-loaded mesoporous silica nanoparticles (CUR@MSNs) incorporated into Poly-ε-Caprolactone/Gelatin (PCL/GEL) hybrid were prepared via blend electrospinning and their impact was evaluated on cell adhesion, viability, proliferation and also the expression of senescence markers and stemness genes after a long-term in vitro culturing. The in vitro release findings proved that the MSNs incorporated into the electrospun nanofibers (NFs) allowed a sustained release of CUR. According to MTT and PicoGreen assays, the significant metabolic activity and proliferation of hADSCs were detected on CUR@MSNs-NFs after 14 and 28 days of incubation. Furthermore, CUR@MSNs-NFs showed better adhesion and spreading of hADSCs compared to other types of NFs. The sustained and prolonged delivery of CUR inhibited the stem cell senescence through the down-regulation of p16INK4A and up-regulation of hTERT. It also led to an increased stemness potency in growing hADSCs on the fibers. These results confirmed that the nanofiber-based sustained drug delivery system might provide a promising approach in designing highly programmable culture platforms to generate sufficient numbers of biologically functional hADSCs for clinical translation.


Asunto(s)
Curcumina , Nanofibras , Nanopartículas , Proliferación Celular , Humanos , Dióxido de Silicio , Células Madre
7.
Asian Pac J Cancer Prev ; 19(6): 1717-1720, 2018 Jun 25.
Artículo en Inglés | MEDLINE | ID: mdl-29938471

RESUMEN

Objective: Interleukin-6 (IL-6) is an inflammatory cytokine shown to be a strong factor for growth, proliferation and metastasis with many malignancies. The promoter single nucleotide polymorphism (SNPs) -174G>C (rs1800795) can alter the transcriptional pattern of this gene. The present study was aimed at assessing effects of the IL-6 (rs1800795) SNP on risk of benign prostate hyperplasia (BPH) and prostatic adenocarcinoma (PCa). Methods: The project was performed on 112 men with PCa, 118 with BPH and 250 healthy controls. After DNA extraction, genotyping of IL-6 (rs1800795) was performed using PCR TaqMan Allelic Discrimination (ABI MGB). Results: The G allele frequency for rs1800795 of the IL-6 gene was 74.1%, 68.6% and 67% in PCa patients, BPH patients and healthy men, respectively. PCa and control groups showed significant differences (P =0.030, OR = 1.73, 95% CI: 1.05-2.21). The GG genotype was more frequent in the PCa group, whereas the GC genotype was more common in the BPH in comparison to other groups. Conclusion: The current study identified IL-6 -174G>C (rs1800795) as a significant predictor of susceptibility for prostate cancer and bone metastasis in a northwest Iranian population.


Asunto(s)
Adenocarcinoma/patología , Neoplasias Óseas/secundario , Predisposición Genética a la Enfermedad , Interleucina-6/genética , Polimorfismo de Nucleótido Simple , Hiperplasia Prostática/patología , Neoplasias de la Próstata/patología , Adenocarcinoma/epidemiología , Adenocarcinoma/genética , Anciano , Biomarcadores de Tumor/genética , Neoplasias Óseas/epidemiología , Neoplasias Óseas/genética , Estudios de Casos y Controles , Femenino , Estudios de Seguimiento , Humanos , Irán/epidemiología , Masculino , Persona de Mediana Edad , Pronóstico , Regiones Promotoras Genéticas , Próstata/metabolismo , Hiperplasia Prostática/epidemiología , Hiperplasia Prostática/genética , Neoplasias de la Próstata/epidemiología , Neoplasias de la Próstata/genética
8.
Biomed Pharmacother ; 105: 773-780, 2018 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-29909345

RESUMEN

The purpose of this study was to investigate the efficiency of a natural flavonoid, Chrysin (Chr), encapsulated in PLGA-PEG nanoparticles (NPs) for the modulation of macrophage polarity from the pro-inflammatory M1 to anti-inflammatory M2 phenotype. The synthetized NPs were characterized using FTIR, DLS and FE-SEM. MTT assay was used to assess the toxicity of different concentration of Chr-encapsulated NPs on LPS/IFN-γ stimulated peritoneal exudate macrophages. To investigate the repolarization efficiency of Chr-encapsulated NPs, real-time PCR was applied to measure M1 (iNOS and SOCS3) and M2 (Arg1 and Fizz) markers expression. Also, the relative mRNA and protein expression levels of pro-inflammatory cytokines including IL-6, IL-1ß and TNF-α were investigated in M1 macrophages treated with Chr-encapsulated NPs. Findings revealed that the Chr-encapsulated NPs with spherical shape and an average diameter of 235 nm were considerably less toxic to the macrophages. Additionally, the nano-formulated Chr efficiently showed a reduction in M1 markers and an increase in M2 markers levels than free Chr. Furthermore, macrophage phenotype switching by PLGA-PEG encapsulated Chr NPs significantly suppressed LPS/IFN-γ induced inflammation by a remarkable reduction in pro-inflammatory cytokine levels, TNF-α, IL-1ß, and IL-6. Convincingly, the results revealed that PLGA-PEG encapsulated Chr based drug delivery system might be introduced into biomaterials to fabricate bioactive smart multifunctional nanocomposites with macrophage repolarization activities for regenerative medicine purposes.


Asunto(s)
Adyuvantes Inmunológicos/farmacología , Polaridad Celular/efectos de los fármacos , Portadores de Fármacos/química , Flavonoides/farmacología , Macrófagos Peritoneales/efectos de los fármacos , Nanocápsulas/química , Polietilenglicoles/química , Poliglactina 910/química , Adyuvantes Inmunológicos/administración & dosificación , Animales , Polaridad Celular/inmunología , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Citocinas/inmunología , Composición de Medicamentos , Liberación de Fármacos , Flavonoides/administración & dosificación , Regeneración Tisular Dirigida , Macrófagos Peritoneales/inmunología , Ratones Endogámicos C57BL , Propiedades de Superficie
9.
Artif Cells Nanomed Biotechnol ; 46(8): 2013-2021, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29183161

RESUMEN

The aim of this study was to evaluate the efficiency of using a natural substance, curcumin, encapsulated in CD44-targeting hyaluronate-polylactide (HA-PLA) nanoparticles (NPs) for the modulation of macrophage polarity from the pro-inflammatory M1 to anti-inflammatory M2 phenotype. For this purpose, the characterization of the NPs was monitored using 1HNMR, FTIR, DLS and FE-SEM. The effects of curcumin-encapsulated HA-PLA NPs on the viability of LPS/IFN-γ stimulated peritoneal macrophages were determined using MTT assay. The cellular uptake of free curcumin and nano-formulated curcumin was assessed using confocal microscopy. Also, the expression levels of iNOS-2 (M1 marker), Arg-1 (M2 marker) and also pro-inflammatory cytokines were measured by real-time PCR. Data showed that the nano-formulated curcumin with spherical shape, an average diameter of 102.5 nm and high cellular uptake was significantly less toxic to peritoneal macrophages. Furthermore, the nano-formulated curcumin effectively indicated a reduction in iNOS-2 and an increase in Arg-1 levels than free curcumin. The change in macrophage phenotype by curcumin-encapsulated HA-PLA NPs could suppress the inflammation in LPS/IFN-γ stimulated macrophages as evidenced by a major reduction in pro-inflammatory cytokines. Conclusively, the results suggested that the curcumin formulation with CD44-targeting HA-PLA NPs might be a promising platform for the treatment of inflammatory diseases.


Asunto(s)
Polaridad Celular/efectos de los fármacos , Curcumina , Sistemas de Liberación de Medicamentos/métodos , Receptores de Hialuranos/metabolismo , Ácido Hialurónico , Macrófagos Peritoneales/metabolismo , Nanopartículas/química , Animales , Curcumina/química , Curcumina/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Ácido Hialurónico/química , Ácido Hialurónico/farmacología , Macrófagos Peritoneales/patología , Ratones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...